Skip to main content

Table 3 HLA-type for donor and patients

From: Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma

Donor A2,24 B15,44 DR1,4
Patient 1 A2 B51,60 DR13
Patient 2 A2 B15,27 DR3,4
Patient 3 A2,3 B8,44 DR3,4
Patient 4 A3,32 B7,44 DR12,15
Patient 5 A1,29 B44 DR7,13
Patient 6 A2,11 B7,60 DR4,13
Patient 7 A26,32 B51,62 DR4
Patient 8 A1,24 B8,18 DR3,13
Patient 9 A2,3 B7,51 DR1,15
Patient 10 A24,29 B35,44 DR7,13
Patient 11 A2,24 B27,51 DR11,12
Patient 12 A2,24 B7 DR4,5